Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis

Immunotherapy (IO)-based combination therapies have emerged as the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC) among patients classified as intermediate and poor risk. However, in the favorable risk group, the available data remains less compelling. This study...

Full description

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2024-01, Vol.122, p.102667-102667, Article 102667
Main Authors: Bolek, Hatice, Yekedüz, Emre, Ürün, Yüksel
Format: Article
Language:English
Subjects:
Carcinoma, Renal Cell - pathology
Disease Progression
Humans
Kidney Neoplasms - pathology
Protein Kinase Inhibitors - therapeutic use
Retrospective Studies
Sunitinib - therapeutic use
Tyrosine Kinase Inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy (IO)-based combination therapies have emerged as the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC) among patients classified as intermediate and poor risk. However, in the favorable risk group, the available data remains less compelling. This study aims to assess and compare the effectiveness of IO-based combination therapies versus tyrosine kinase inhibitor (TKI) monotherapy in patients with favorable risk group according to the International mRCC Database Consortium (IMDC). Recent update data from phase-III RCTs of IO-based combinations approved by the Food and Drug Administration were used. Studies that provided data on progression free survival (PFS) and overall survival (OS) of IMDC favorable risk were included in the analysis. A cohort of 1,088 patients categorized within the IMDC favorable risk group was enrolled for analysis. In comparison to sunitinib, the combination of immunotherapy (IO) and tyrosine kinase inhibitor (TKI) exhibited a reduction in the risk of disease progression (HR = 0.67, 95 % CI: 0.55-0.82; p 
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2023.102667